Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non Operating Income (2021 - 2025)

Historic Non Operating Income for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $1.6 million.

  • Amylyx Pharmaceuticals' Non Operating Income fell 4450.46% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year decrease of 4937.26%. This contributed to the annual value of $12.6 million for FY2024, which is 1871.57% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Non Operating Income stood at $1.6 million, which was down 4450.46% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Non Operating Income ranged from a high of $4.5 million in Q4 2023 and a low of -$3.3 million during Q2 2021
  • For the 5-year period, Amylyx Pharmaceuticals' Non Operating Income averaged around $1.7 million, with its median value being $1.9 million (2025).
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Non Operating Income skyrocketed by 861034.48% in 2022, and later plummeted by 6056.89% in 2025.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Non Operating Income stood at -$29000.0 in 2021, then soared by 8610.34% to $2.5 million in 2022, then skyrocketed by 84.04% to $4.5 million in 2023, then tumbled by 45.55% to $2.5 million in 2024, then crashed by 33.64% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.4 million for Q2 2025, and $1.9 million during Q1 2025.